Chest
-
Bronchology Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Post-extubation stridor is a life-threatening condition. A variety of their causes has been established and includes obstructed secretion, vocal cord edema, vocal cord dysfunction, and tracheomalacia. In this report, we report herein a rare incidence of post-extubation stridor caused by obstructive fibrinous tracheal pseudomembrane (OFTP). ⋯ In conclusion, this report highlights the potential fatal complication of considering OFTP in patient presenting with dyspnea and inspiratory stridor after extubation, and the physician should alert and perform bronchoscopy for the precise diagnosis to allow early detection.Reference #1: Deslee G, Brichet A, Lebuffe G, Copin MC, Ramon P, Marquette CH (2000) Obstructive fibrinous tracheal pseudomembrane. A potentially fatal complication of tracheal intubation. Am J Respir Crit Care Med 162:1169-1171DISCLOSURE: The following authors have nothing to disclose: Narongwit NakwanNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:00 AMPURPOSE: Biomass smoke exposure is a risk factor for developing chronic obstructive pulmonary disease (COPD). Little is currently known concerning clinical differences between COPD due to tobacco and to biomass smoke. The purpose of this study was to search for clinical differences between both types of disease ⋯ Pilar Sanjuán: Consultant fee, speaker bureau, advisory committee, etc.: Almirall, Astra-Zeneca, Boehringer-Ingelheim Rafael Golpe: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, GSK, Astra-Zeneca, Boehringer-Ingelheim, Almirall Luis Pérez-de-LLano: Grant monies (from industry related sources): Almirall, Consultant fee, speaker bureau, advisory committee, etc.: Almirall, Novertis, Astra-Zeneca, Boehringer-Ingelheim, GSK, Menarini Esteban Cano: Consultant fee, speaker bureau, advisory committee, etc.: GSK Olalla Castro-Añon: Consultant fee, speaker bureau, advisory committee, etc.: NovartisNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Sirolimus, also known as rapamycin, is an immunosuppressant drug introduced in 1999 as prophylaxis or treatment of acute rejection in transplant recipients with other immunosuppressive drugs. In recent years it has been recognized sirolimus-associated pulmonary toxicity with a wide spectrum of clinical pictures within there have been reports of interstitial pneumonitis, diffuse alveolar haemorrhage, and bronchiolitis obliterans organizing pneumonia. ⋯ The following authors have nothing to disclose: Luciana Molinari, Teresita Rosenbaum, Patricia Aruj, Clarisa Alvarez, Cristina Aguirre, Edgardo SobrinoNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Mild hypoxia has been seen in approximately one third of patients with chronic liver disease (CLD). Hepatopulmonary syndrome (HPS) is an important cause in a patient with hypoxemia and CLD. HPS in patients with CLD modifies the line of management and determines the prognosis of the disease. HPS is characterized by arterial de-oxygenation, intrapulmonary vascular dilatation (IPVD) in the setting of liver disease. This study was undertaken to assess the prevalence of HPS and to find predictive value of respiratory parameters in the diagnosis of HPS in patients admitted for liver transplant evaluation. ⋯ The following authors have nothing to disclose: Amrut Sindhu Sanikop, Raj SinghNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To outline the resource use and costs a U.S. health plan can anticipate during the evaluation and first year of treatment of a CTEPH patient ⋯ Vijay Joish: Employee: employee of bayer sponsor of study Christine Divers: Employee: employee of bayer sponsor of study Chakkarin CBurudpakdee: Consultant fee, speaker bureau, advisory committee, etc.: consultant of bayer sponsor of study Anshul Shah: Consultant fee, speaker bureau, advisory committee, etc.: consultant of bayer sponsor of study Stephen Mathai: Consultant fee, speaker bureau, advisory committee, etc.: consultant to bayer sponsor of studyNo Product/Research Disclosure Information.